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1. Introduction
Chronic chagasic cardiomyopathy (CCC) is the most serious manifestation of the chronic form
of Chagas’ disease and constitutes the most common type of chronic myocarditis in the world
[1-5]. Chagas’ disease, a chronic illness caused by the flagellate parasite Trypanosoma cruzi (T.
cruzi), was first described in 1909 by the Brazilian physician Carlos Chagas [6]. The insect
vectors of the disease are present throughout most of South and Central America, and their
zone of distribution extends across the southern United States [7]. It was estimated by year
2000, that in endemic areas 40 million people were considered to be at risk of infection, being
20 million already infected. Every year near 200,000 new cases are expected to happen, and
21,000 deaths per year occur [8].
Although always considered to be confined to Latin America, due to migratory movements
from endemic countries to Europe and North America, Chagas’ disease is being detected more
frequently in developed countries. Europe is estimated to have from 24,001 to 38,708 (lower
or upper limit of estimate, respectively) immigrants with T. cruzi infection [1]. In the United
States 6 autochthonous cases, five transfusion related cases and five transplant associated cases
have been reported, but migratory movements still remain the main source of Chagas’ disease.
It has been estimated that around 89,221 to 693,302 infected Latin Americans migrated to the
United States in the period 1981 to 2005 [3].
Two phases of the disease can be distinguished: (1) acute phase, with transiently high con‐
centration of parasites in tissue and blood, nonspecific symptoms, and a 5% myocarditis
incidence, lasting 4 – 8 weeks; and (2) chronic phase, lasting lifelong. Chronic phase can be
presented as indeterminate form, characterized by lack of symptoms and normal ECG and
normal radiographic examination of the chest, esophagus and colon. Approximately 60 – 70%
of patients remain in this form for the rest of their lives. Only 20 - 40% of infected individuals,
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10 - 30 years after the original acute infection, will develop cardiac, digestive or mixed form
of the disease, characterized by the appearance of megavicera (dilated cardiomyopathy,
megaesophagus and/or megacolon). It poses a substantial public health burden due to high
morbidity and mortality [3, 7, 9].
CCC is manifested by a chronic, diffuse, progressive fibrosing myocarditis that involves not
only the working myocardium but also the atrioventricular (AV) conduction system, auto‐
nomic nervous system and microcirculation [10 - 12]. This leads to cardiomegaly, cardiac
failure, arrhythmias, thromboembolism, and death [11]. Colon and esophagus are also
commonly affected by Chagas’ disease, being megacolon with constipation and megaesofagus
with achalasia also features of the disease [7].
2. Pathogenesis of Chagas’ myocarditis
Milei et al. proposed a combined theory that could explain the pathogenic mechanism in
chronic chagasic myocarditis [2, 13] that has been previously reviewed by us [14]. This
hypothesis is based on three ingredients: the parasite, host immune system and fibrosis. These
ingredients are proposed as being the primary causative agents of damage on myocardial
tissue, conduction system, autonomic ganglia and nerves and microvasculature.
2.1. First ingredient: The parasite
The role of T. cruzi in the chronic phase has been previously underestimated due to the fact
that its presence was believed to be scarce and unrelated to the inflammatory infiltrate present
at this stage. Nowadays, the involvement of the parasite in the chronic phase has been well
documented. Using dissimilar methods, different authors demonstrated either the persistence
of T. cruzi or parasite antigens in mice [15], the parasite DNA sequence amplified by the
polymerase chain reaction (PCR) [16, 17], T. cruzi antigens from inflammatory lesions in human
chagasic cardiomyopathy [18], or the immunohistochemical finding of the parasite in endo‐
myocardial biopsies with PCR confirmation [19]. This would suggest a direct role for the
parasite in the perpetuation of myocardial inflammation. In other words, the antigen stimu‐
lation would persist throughout the chronic stage, even though the parasites are not morpho‐
logically detectable by light microscopy [20].
The role of parasitemia is more controversial. High parasitemia correlated with severity of
disease in one report [21], but showed no association in another [22]. Interestingly, it has
been observed that immunosuppression reactivates rather than ameliorates the disease, as
seen in patients receiving immunosuppressive therapy to prevent transplant rejection and
in  AIDS  patients.  Accordingly,  many  experimental  models  where  strains  of  genetically
manipulated mice  lacking  various  immune functions  showed increased susceptibility  to
develop the disease [23].
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2.1.1. Life cycle of Trypanosoma cruzi (Figure 1)
When a reduviid bug feeds from an infected mammal, it takes up circulating trypomastigotes,
which reach then the bug’s gut. There, they differentiate to amastigotes, which proliferate and
start to differentiate into epimastigotes. In this process, when amastigote is still sphere-shaped
but has developed its flagellum, some authors call this stage spheromastigotes. Then, it
elongates its cell body and flagellum, taking the classical epimastigote shape. At this stage, the
parasite undergoes metacyclogenesis, differentiating in metacyclic trypomastigotes, the
infective form for mammals. When the bug feeds again, it excretes trypomastigotes with feces,
which in turn reach blood torrent through bug’s wound. Trypomastigotes can infect a wide
variety of host cells, within them it differentiate into amastigotes and proliferate. Then, they
can differentiate into trypomastigotes again, reach circulation and infect new cells. If an
uninfected bug feeds from the animal in the moment of parasitemia, cycle starts again [24].
2.1.2. Genetic variability of Trypanosoma cruzi and its relation to its pathogenesis
The genetics of T. cruzi caught the attention of researchers in late 80’ and early 90’. First studies
on variability were performed analyzing electrophoretic variants on cellular enzymes. The
Figure 1. Life cycle of Trypanosoma cruzi
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groups resulting were called zymodemes and were named Z1, Z2, Z3. Only Z2 was associated
with domestic transmission cycle.
THe development of PCR based techniques allowed the study of new variant regions and the
characterization of multiple variants of a great number of genes. All these variants showed
significant correlation with each other, suggesting the existence of two subtypes of T. Cruzi
based on these data [25]. Moreover, T. cruzi II which is clearly linked to human pathology,
being T. cruzi I mainly related to infection of wild sylvatic mammals. Even, applying LSSP-
PCR to the study of the variable region of kinetoplast minicircle from T. cruzi provided
evidence of a differential tissue distribution of genetically diverse T. cruzi populations in
chronic Chagas’ disease, suggesting that the genetic variability of the parasite is one of the
determining factors of the clinical form of the disease [26].
2.1.3. Cell host invasion and intracellular survival by Trypanosoma cruzi
Once T. cruzi reaches blood torrent, it invades a great variety of cells in the host. When
parasiting non phagocytic cells, T. cruzi uses some surface glycoproteins to attach to cell: gp82,
gp30 and gp35/50. All three glycoproteins are known to induce calcium mobilization from
intracellular reservoirs. Gp82 is linked to the phospholipase C (PLC) and inositol 1,4,5 –
triphosphate (IP3). Gp 35/50is associated to increasing intracellular levels of cyclic AMP. On
the other side, cruzipain, a protein known to be secreted by T. cruzi, acts on kininogen and
produces bradykinin, which binds to its receptor, further increasing intracellular calcium.
Increased intracellular calcium produces modifications in cytoskeleton that lead to parasite
endocytosis [27].
In the parasitoforous vacuole, mainly by the action of gp85/TS a glycoprotein with trans-
sialidase action, and TcTox, a protease, the parasite degrades the membrane of the vacuole,
escapes from it and proliferates within the cell [28].
2.1.4. Molecular mimicry
The induction of autoimmunity by similarities between T. cruzi and host epitopes has been
long proposed as a mechanism that leads to tissue damage in the chronic phase of the disease.
Both humoral and cellular autoimmune responses have been described, but we will discuss
them in more detail in the section of immune system. The real importance of molecular mimicry
in the pathogenesis of chagasic myocarditis is still a matter of debate [29].
Although it seems that in some cases this mechanism triggers autoimmunity, in many others,
autoimmunity seems to be an epiphenomenon of cellular destruction, with exposition of
intracellular epitopes not normally exposed to the immune system. This, in turn may activate
autoreactive lymphocytes leading to the appearance of autoantibodies that are not the cause
of damage, rather a consequence [29].
The most important cross reacting epitopes of T. cruzi and the correspondent epitopes in
humans are listed in table 1, as well as the kind of immune response they elicit.
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2.2. Second ingredient: Host immune system
When the three ingredients theory was first proposed [2, 13], second ingredients were mainly
T lymphocytes and macrophages. In the subsequent years some evidence grew about the
participation of humoral immune system through autoantibodies in the pathogenesis. As a
consequence, the whole immune system of the host is now considered as the second ingredient.
As described earlier, mononuclear cells persist in the chronic stage of the disease, contribu‐
ting to the inflammation through its products of secretion or through its own cytotoxici‐
ty  (suppressor  T  cells)  and  cytolytic  action  (macrophages)  [13].  As  previously  stated,
molecular mimicry may be the main explanation of autoimmunity, triggering both cellular
and humoral autoreactivity [29]. Figure 2 summarizes the most important immune events
in CCC pathogenesis.
Parasite antigen Human Antigen Immune reaction
B13 Cardiac myosin heavy chain Autoantibodies
Autoreactive T cells
R13 (ribosomal protein) Ribosomal protein
β1-adrenergic receptor
M2-muscarinic receptor
38-kDa heart antigen
Autoantibodies
Ribosomal protein PO β1-adrenergic receptor Autoantibodies
FL-160 47-kDA neuron protein Autoantibodies
Shed acute-phase antigen (SAPA) Cha antigen Autoreactive T cells
TENU2845/36 kDa Cha antigen Autoantibodies
Calcireticulin Calcireticulin Autoantibodies
Autoreactive T cells
Galactosyl-cerebrosides Galactosyl-cerebrosides Autoantibodies
Unknown Neurons, liver, kidney, testis Autoantibodies
Sulphated glycolipids Neurons Autoantibodies
150-kDa protein Smooth and striated muscle Autoantibodies
Cruzipain Cardiac myosin heavy chain
M2-muscarinic receptor
Autoantibodies
Microsomal fraction Heart and skeletal muscle Autoantibodies
Cytoskeleton 95-kDa myosin tail Autoantibodies
SRA Skeletal muscle Ca2+ dependent SRA Autoantibodies
MAP MAP (brain) Autoantibodies
Soluble extract Myelin basic protein Autoantibodies
Autoreactive T cells
55-kDa membrane protein 28-kDa Lymphocyte membrane protein Autoantibodies
Table 1. Examples of cross-reacting epitopes [12, 29]
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Figure 2. A. The immune pathogenesis of Chagas disease in indeterminate patients. The presence on numerous down
regulating mechanisms shift the response towards an anti-inflammatory profile. B. The immune pathogenesis of Cha‐
gas disease in CCC patients. Cells evolve towards a proinflammatory profile, with development of autoimmunity.
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2.2.1. Innate immunity
In recent years innate immunity came to the attention of researchers of Chagas’ disease
pathogenesis. The role of NK cells has been particularly studied in early and late indeterminate
phases of the disease and in CCC patients. In early indeterminate patients, compared to non
infected people, increased values of pre-natural killer (NK)-cells (CD3- CD16+ CD56-), and
higher values of proinflammatory monocytes (CD14+ CD16+ HLA-DR++) were found. The
higher values of activated B lymphocytes (CD19+ CD23+) contrasted with impaired T cell
activation, indicated by lower values of CD4+ CD38+ and CD4+ HLA-DR+ lymphocytes, a lower
frequency of CD8+ CD38+ and CD8+ HLA-DR+ cells; a decreased frequency of CD4+ CD25HIGH
regulatory T cells was also observed. All these data suggest a rather proinflammatory profile
[30]. This profile may be useful to limit parasitemia and confine infection to tissues. In fact, it
has been demonstrated that NK cells are important in defence against the spread of parasitic
infection [31], and are an important source of INF-γ, a key cytokine to activate macrophages
and help with parasite clearance [32].
In late indeterminate phase, CD3-CD16+CD56+ and CD3-CD16+CD56DIM NK cells are increased
but are in normal range in CCC patients, suggesting a protective role for them [33]. NK cells
showing CD56DIM may play a role in the down modulation of cytotoxic deleterious T CD8+
response reported in CCC patients [34].
Monocytes display different cytokine profile. In indeterminate patients they produce more
IL-10 [35] while in CCC patients they produce more TNF-α [36], leading to a proinflammatory
profile that could be responsible for chronic myocarditis. Conversely in vitro experiments
culturing moncytes from indeterminate and CCC patients showed a predominant production
of INF-γ in the former and IL-10 in the later [37]. Also, monocytes of indeterminate patients
showed downregulation of Fc-γR, TLR and CR1 molecules, related to an impaired phagocytic
capacity [38].
Toll-like receptors (TLR) are also implied in the response to acute infection with T. cruzi.
TLR-2 has been shown to recognize GPI surface molecules from the parasite. In vitro and
in vivo studies have demonstrated that macrofages stimulated with GPIs through TLR-2/
CD14 receptors produce NO, TNF-α and IL-12 [39]. Toll-like receptor 4 (TLR4)-deficiency
genotype  D299G/T399I  occurred  more  frequently  in  asymptomatic  (14.8%)  than  CCC
patients. TLR1-I602S, TLR2-R753Q, TLR6-S249P, and MAL/TIRAP-S180L did not associate
with CD or  CCC.  These findings indicate  that  curbed TLR4 activation might  be  benefi‐
cial in preventing CCC [40].
A key role of complement in infection control has been clearly established. The complement
activating molecules C1q, C3, mannan-binding lectin and ficolins bound to all strains analysed;
however, C3b and C4b deposition assays revealed that T. cruzi activates mainly the lectin and
alternative complement pathways in non-immune human serum [41]. Mannose-binding lectin
(MBL) initiates complement on Trypanosoma cruzi through the MBL-associated serine protease
2 (MASP2). MASP2 polymorphisms, specialy g.1961795C, p.371D diplotype (short CD),
occurred at a higher frequency among symptomatic patients, compared with the indeterminate
group, highlighting the importance of complement in the pathogenesis of CCC [42].
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2.2.2. Cellular adaptative immunity
The role of immune cells in the pathogenesis of Chagas’ heart disease has been de dominant
hypothesis for many years. The paucity of parasite cells in the inflamed myocardium and the
presence throughout the evolution of the disease of macrophages and lymphocytes in patched
infiltrates lead to this hypotesis. As early as in 1929, Magariños Torres, observing those
infiltrates postulated an “allergic” mechanism for CCC. Further, Mazza and Jörg followed this
thought and supported the “allergic” theory [13].
The study of circulating lymphocytes in peripheral blood of chagasic patients showed an
increase in the percentages and actual numbers of double-positive cells of the phenotype CD3+/
HLA-DR+, as well as decrease in the percentage of CD45RA+/CD4+ and CD45RA+/CD8+ T
cells, indicating greater numbers of activated T cells circulating. Consistent parallel increases
were seen also in the B lymphocyte subset which stained double-positive for CD19/CD5 [43].
These results were similar for both indeterminate and CCC patients. Moreover, T cells from
chagasic patients do not express the co-stimulatory molecule CD28 [44] but express high levels
of HLA-DR molecules [45]. Some interesting differences were demonstrated between inde‐
terminate and CCC patients. CD28- T cells in indeterminate patients showed expression of
CTLA-4, which recognizes the same ligands as CD28, but instead of inducing cell activation it
causes down modulation of T cells. On the contrary, T cells in CCC patients do not up-regulate
CTLA-4 [46].
Monocytes from indeterminate patients, when infected in vitro with T. cruzi, express low levels
of HLA-DR and high levels of CD80, a ligand for CTLA-4 [47]. The interaction of these
monocytes with CTLA-4+ T cells leads to the expression of IL-10, a cytokine known to down-
modulate inflammatory responses [35]. This is not observed in CCC patients. CD28- T cells,
not expressing CTLA-4, express TNF-α and INF-γ [44].
In the same direction, CD4-CD8- γδ T cells are found to be increased in indeterminate patients
compared with CCC ones. These cells are also linked to the production of IL-10 and a down
modulatory effect on inflammation [48].
Cells infiltrating myocardium have also been studied. As demonstrated with immunostaining
of endomyocardial biopsies by our group, leukocytes infiltrating myocardium in Chagas’
disease were approximately 50% macrophages, and 50% lymphocytes, mainly T lymphocytes
[49]. Further immunohistochemical characterization of these cells with CD45R for lympho‐
cytes, CD20 and lambda and kappa light chains for B lymphocytes, CD45R0 for T lymphocytes
and CD68 for macrophages, confirmed these findings [2].
Autoreactive T cells have caught the attention of many investigators. In experimental models,
CD4+ T cells from infected mice showed a proliferative response to the exposition to human
cardiac myosin heavy chain and to T. cruzi B13 protein. They also arrested the beating of fetal
heart cells and, more importantly, induced myocarditis in immunized mice and promoted
rejection of transplanted normal hearts in the absence of T. cruzi [50]. Also, it has been described
that T cells infiltrating the myocardium of chagasic patients cross react with human cardiac
myosin heavy chain and to T. cruzi B13 protein and express high levels of INF-γ and low levels
of IL-4, switching to a Th1 profile [51].
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A second group of autoreactive T cells have been characterized, that react to Cha antigen in
human heart. Cha antigen is a protein in human myocardium of unknown function that is
recognized sera from chagasic patients. When anti-Cha T cells are transferred to non infected
mice, they cause myocarditis and stimulate anti-Cha autoantibodies production [52].
In recent years, a newly described T cell, named Treg, has come to attention in relation to
Chagas’ disease pathogenesis. These cells are characterized by the expression of CD4 and
CD25. Treg cells are increased in indeterminate patients compared to CCC, which correlates
negatively with levels of activated CD8+ [33]. In a recent review on the role of these cells on
the pathogenesis of CCC it is highlighted that indeterminate patients have a higher frequency
of Treg cells, suggesting that an expansion of those cells could be beneficial, possibly by
limiting strong cytotoxic activity and tissue damage. Indeterminate patients also show an
activated status of Treg cells based on low expression of CD62L and high expression of CD40L,
CD69, and CD54 by cells from all chagasic patients after T. cruzi antigenic stimulation.
Moreover, there was an increase in the frequency of the population of Foxp3+ CD25HighCD4+
cells that was also IL-10+ in the IND group, whereas in the cardiac (CARD) group, there was
an increase in the percentage of Foxp3+ CD25High CD4+ cells that expressed CTLA-4 [53].
An additional mechanism is the bystander activation. This is the activation of autoreactive
lymphocytes by antigen presenting cells in a proinflammatory environment [54]. This kind of
autoreactive T cells activation has been described in Chagas’disease [55].
2.2.3. Humoral adaptative immunity
The importance of humoral immunity in controlling T. cruzi acute infection has been clearly
established. Mice lacking B lymphocytes rapidly succumb to infection [56]. But the fact that
attracted most attention from researchers is the production of a wide variety of autoantibodies.
The first autoantibody to be described was one that reacted to endocardium, blood vessels and
interstitium of skeletal muscle (EVI) [57], but was the same group of investigators who
recognized the heterophil nature of the antibody and realised that had no pathogenic role [58].
Another autoantibody, studied by our group, was anti-laminin antibody [59, 60]. These
antibodies were shown to react against T. cruzi amastigotes and trypomastigotes and human
laminin [61] and deposition of this antibody in marked thickened basement membranes of
myocytes, endothelial cells, and vascular smooth muscle cells was shown by us with light
microscopy, electron microscopy and immunohistochemical techniques in endomyocardial
biopsies of chagasic patients [62] but then we found that only 50% of patients had the antibody
on their sera and no correlation with disease severity could be established [59].
Anti-myosin antibodies are postulated by some authors to be generated through molecular
mimicry with two T. cruzi antigens: B13 protein [63] and cruzipain [64, 65]. Although cruzipain
antibodies mainly react to skeletal muscle myosin, they can cause conduction disturbances
when transferred to uninfected mice and, when transferred to pregnant animals, they caused
conduction disturbances in pups [65]. On the other hand, immunossuppresed mice did not
mount any humoral response when immunized with myosin but still develop myocarditis [66].
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This fact made some authors doubt on the molecular mimicry hypothesis and rather consider
antibodies to myosin a consequence of myocyte damage [67].
Antibodies that react with muscarinic receptors are also being intensely studied. In early 1990’s
IgG from chagasic patients was observed to bind to muscarinic M2 receptors and activate them
[68]. These anti-muscarinic antibodies were found to increase intracellular cGMP and decrease
cAMP [69] and were positively related to the presence of dysautonomia [70]. These antibodies
also causes accumulation of inositol phosphate and nitric oxide synthase stimulation, with a
negative inotropic effect on myocardium [71]. As mentioned before, anti-muscarinic autoan‐
tibodies are positively related to the presence of dysautonomia [70], the presence of achalasia
in chagasic patients [72], sinus node dysfunction [73], but are not related with the degree of
myocardial dysfunction [73, 74], nor with the presence of brain lesions [75]. In fact patients
with cardiomyopathy and left ventricular dysfunction but without autonomic dysfunction
show low levels of anti-muscarinic antibodies [76].
Autoantibody Hypothetic pathogenic role Reference
Anti-Cerebroside Probably related to neurologial symptoms [77]
Anti-Gal Apparently protective [78]
Anti-Brain Microtubules Unknown [79]
Anti-Ribosome Unknown [80, 81]
Anti- UsnRNPs Unkwnown [82]
Anti-Sulfatides May cause myocarditis and induce arrhythmias [83]
Anti-Galectin-1 Increased in CCC patients [84]
Anti-Cha R3 Specific of CCC [85]
Anti-Desmoglein-1 Related to Penphigus foliaceum [86]
Anticardiolipin Unknown [87]
Anti- TrkA, TrkB and TrkC Prevents apoptosis of neurons and helps cellular invasion [88]
Anti-MBP Related to gastrointestinal form [89]
Table 2. Less studied autoantibodies in Chagas’ disease
Antibodies against β1-adrenergic receptors are also intensely studied. Described in early 1980’s
[90] these antibodies increased cAMP in mouse atrial fibers, increasing the release of PGE2 and
TXB2 causing diminished contractility [91]. Increased cAMP activates PKA and then increases
the intracellular calcium concentration. This causes in turn inhibition of the Na+/K+-ATPase
and stimulates Ca2+-ATPase activity leading to intracellular depletion of K+ and further
increase in Ca2+. These alteration alter contractility and electric impulse generation and
conduction [92]. Antiadrenergic autoantibodies titers could not be related to the severity of
left ventricular dysfunction [74] and patients with overt cardiomyopathy but without auto‐
nomic dysfunction show low leves of these antibodies [76]. Antibodies against β2-adrenergic
receptors have also been described but are mainly related to megacolon [93].
Antibodies against atrio-ventricular (AV) node and sinus auricular node tissues have been
studied as markers of chronic cardiopathy condition. When compared in chronic chagasic
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cardiopathy patients, non-chagasic cardiopathy patients, indeterminate chagasic subjects,
healthy blood donors as controls, they more frequently found in chronic chagasic cardiopathy,
but not enough to be good markers for chagasic cardiopathy group. Besides, no clear associ‐
ation with complex rhythm or conduction aberrations was found [94].
Many other autoantibodies have been described (table 2) but are not so widely studied and
their role in pathogenesis of chagasic myocarditis is not clear.
2.2.4. Genetic factors
Human Leucocyte Antigen (HLA) have show some relation to de development of CCC. HLA-
B40 and Cw3 combination was protective for CCC [95], as resulted DRB1*14, DQB1*0303 [96],
HLA-DQB1*06 [97] and HLA-A68 [98]. On the other hand, HLA-C*03 [99], DRB1*1503 [100],
DRB1*01, DRB1*08, DQB1*0501 [96] and HLA-DR16 alelles [98] were positively related to the
development of CCC.
A number of other genes related to immune system have been studied in order to determine
their relation to a predisposition to develop CCC. In table 3 we list those positively related to
the appearance of CCC [101].
Gene Polymorphism
CCL2/MCPI - 2518
CCR5 + 53029
TNF-α - 308G/A, -238G/A, -1031T/C
LT-α + 80A/C, + 252A/G
BAT-1 - 22C/G, - 348C/T
NF-kB - 62, - 262
IL-1β - 31, + 3954, + 5810
IL-1RN +11100T/C
IL-4 -509C/T
IL-10 - 1082G/A
IL-12β + 1188A/C
INF-γ +874T/A
MAL/TRIAP S180L
MCP-1 -2518α/G
MIF -174G/C
TGF-β1 +10T/C
Table 3. Genetic polymorphisms related to CCC. Adapted from [101, 102].
2.2.5. The cytokines and chemokines
Although proinflammatory cytokines seem to be necessary for controlling parasitemia during
acute phase of the disease [101], CCC patients display a rather proinflammatory cytokine while
indeterminate patients display a down modulator one. CCC patients have increased levels of
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TNF-α and CCL2 than indeterminate patients [103, 104]. Infiltrating macrophages from CCC
patients express INF-γ, TNF-α and IL-6 but show low levels of IL-2, IL-4 and IL-10 [105-107].
Also CCR5, CXCR3 and CCR7 and their ligands are increased in hearts of CCC patients, as
well as monocytes expressing CXCR3, CCR5, CXCL9 and CCL5 [101]. It has been shown that
INF-γ and CCL2 induce myocytes to secrete arial natriuretic factor and cause hyperthrophy
[108], and IL-18 and CCR7 ligands, which are increased in CCC, cause cardiomyocyte hyper‐
throphy and fibrosis [109-111]. Cultures of peripheral blood mononuclear cells from patients
with moderate and severe cardiomyopathy produced high levels of TNF-α, IFN-γ and low
levels of IL-10, when compared to mild cardiomyopathy or cardiomyopathy-free patients.
Flow cytometry analysis showed higher CD4+IL-17+ cells in peripheral blood mononuclear
cells cultured from patients without or with mild cardiomyopathy, in comparison to patients
with moderate or severe cardiomyopathy, reflecting a relative protective effect of IL-10 and
IL-17 compared with INF-γ and TNF-α [112]. In another experiment in which CD8+ in culture
were stimulated with trypanosomal antigens, those cells froms patients with CCC produced
larger amounts of INF-γ and TNF-α than those obtained from indeterminate patients [113].
2.3. The third ingredient: Fibrosis
Fibrosis is one of the most striking characteristics of CCC. In our experience with endomyo‐
cardial biopsies, fibrosis had replaced between 8,2 and 49% of contractile myocardium, with
only one patient having less than 10% [49]. In our experience with autopsies of hearts, fibrosis
was more extensive in conduction system than in contracting myocardium [2]. The deposition
of laminin in extracellular and basement membranes has been implicated in the pathogenesis
of inflammatory process, as laminin is able to bind proinflammatory citokines [114]. The
inflammatory infiltrate in CCC is related to the production of citokines such as INF-γ, TNF-
α, IL-18, CCL2 and CCL21, that may have modulator actions on fibrotic process [101].
3. Pathophysiological consequences of myocarditis
With the perpetuation of inflammation, necrosis and scarring fibrosis, damage to all histolog‐
ical components of myocardium occurs. Damage to contracting myocardial fibers determines
contractile failure as well as electrophysiological disturbances. Conduction system, nervous
autonomic system and microvasculature are also damaged and as a consequence they cause
further damage to contractile myocardium and produce electrical instability.
3.1. Dysautonomia
As early as 1922 Carlos Chagas noted that the chronotropic response to atropine was altered in
chagasic patients [115], but it was not until late 1950’s that Köberle published his works show‐
ing impressive neuronal depopulation in microscopic sections obtained from the intercaval atrial
strip in chagasic patients using a standardized technique of cardiac intramural neuronal counting
developed by himself [116, 117]. These findings led to the “neurogenic hypothesis” [118], which
explained all megas in Chagas’ disease as a consequence of neuronal depletion.
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Although  many  other  authors  claimed  to  have  confirmed  this  finding  [119,  120],  other
authors  called  to  attention  about  the  criteria  used  to  diagnose  neuronal  depletion  be‐
cause of  the great  variability  in  the number of  neurons in autonomic ganglia  [121]  and
they also remark that the only right criterion to establish neuronal depletion is the presence
of proliferation of satellite cells,  with the formation of Terplan’s nodules, a characteristic
lesion described as proliferating satellite cells which replace degenerating neurons, forming
nodular structures.  These lesions,  once considered patognomonic,  can be found in other
cardiomyopathies  [121].  The  same  author  could  not  confirm  the  loss  of  neurons  or
denervation in CCC [122].  Finally,  it  was demonstrated that,  using Terplan’s nodules as
diagnostic  criterion,  CCC  patients  with  heart  failure  has  more  neuronal  depletion  than
patients with dilated cardiomyopathy of other causes [120]. In our experience the neurogan‐
glionic involvement was variable in autopsies of chagasic hearts [11].
According to neurogenic hypothesis [118], early and irreversible damage to the parasympa‐
thetic system during acute phase of the disease causes a cathecolaminergic cardiomyop‐
athy,  but this  point  of  view has been debated and evidence is  contradictory.  Functional
test  performed  in  CCC  patients  demonstrated  impaired  parasympathetic  heart  rate
regulation: metaraminol, phenylephrine and atropine intravenous injections, facial immer‐
sion, Valsalva maneuver, head-up and head-down tilt tests, respiratory sinus arrhythmia,
hand grip, graded dynamic exercise, and spectral analysis of Holter recordings [123-130],
but a carefull  analyasis of these data showed that many patients had normal autonomic
function and most patients had heart failure, that could explain autonomic dysfunction per
se [131]. But the study of indeterminate patients has shown conflicting results. While some
authors could demonstrate impaired autonomic function [132,  133] others could demon‐
strate  that  autonomic  function was  normal  in  patients  without  myocardial  damage and
that abnormalities in autonomic dysfunction was proportional to heart dysfunction, leading
these authors to propose that these abnormalities arise as a compensating mechanism for
the progressive left ventricular dilatation [134, 135]. These findings led to a new “neurogen‐
ic theory”, which considers autonomic dysfunction as secondary to ventricular dilatation
and hemodynamic alterations, but once installed, acts synergistically with parasitism and
inflammation to cause further myocardial damage [136].
3.2. Microvascular damage
Microcirculation abnormalities have been demonstrated in experimental models as well as in
clinical practice [137]. Many investigators have found abnormal myocardial perfusion using
isonitrile-99m-technetium [138] and thallium-201 [139, 140] scintigraphy in chagasic patients
with normal epicardial coronary arteries. Furthermore, the progression of left ventricular
systolic dysfunction is associated with both the presence of reversible perfusion defects and
the increase in perfusion defects at rest [141, 142]. Anatomopathological studies in humans
also provided evidence of microvascular damage in CCC. In late 1950’s first reports showing
collapse of arterioles and intimal proliferation [143] caught the attention of investigators. Also,
microthrombi have been described [144]. In endomyocardial biopsies we also found thickening
of capilary basement membranes [49].
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Additional evidence of microvascular damage was obtained from experimental models.
Vascular constriction, microaneurysm formation, dilatation and proliferation of microvessels
has been demonstrated [145-148].
Many factors have been advocated in the genesis of these lesions. First, the parasite itself.
It  was  shown that  T.  cruzi  produces  a  neuraminidase  that  removes  sialic  acid  from de
surface of endotelial cells. This results in thrombin binding and platelet aggregation [149].
T. cruzi also produces tromboxane A2 (TXA2), specially during amastigote state [150], also
favouring platelet aggregation and vascular spasm. Direct parasitism of endothelial  cells
by T. cruzi has also been demonstrated, and this causes the activation of the NF-kB pathway
increasing  the  expression  af  adhesion  molecules  [151],  and  secreting  proinflammatory
citokines [152] and iNOS [153].
Endothelin-1 (ET-1) is another proposed pathogenic element. Elevated levels of mRNA for
preproendothelin-1, endothelin converting enzyme and endothelin-1 were observed in the
infected myocardium [154], and elevated levels of ET-1 have been found in CCC patients [155].
Mitogen-activated protein kinases and the transcription factor activator-protein-1 regulate the
expression of endothelin-1, and both are shown to be increased in myocardium, interstitial
cells and vascular and endocardial endothelial cells [156]. Besides, treatment with phosphor‐
amidon, an inhibitor of endothelin converting enzyme, decreases heart size and severity of
pathology in an experimental model of Chagas’ disease [157]. Moreover, the use of bosentan,
a dual endothelin A (ETA) receptor and endothelin B (ETB) receptor was accompanied by a
significant increase in parasitemia and tissue parasitism or inflammation and reduced the
infection-associated increase in NOx serum concentration, suggesting that ETA and ETB may
play a role in the control of T. cruzi infection probably by interfering in NO production [158].
Inflammation also produces dysfunction of endothelial cells. Macrophages secrete TXA2 and
platelet activating factor (PAF) that act on endothelium causing vasoconstriction [159].
Endothelial cells infected in vitro with T. cruzi lose their antithrombotic properties in response
to interleukin 1 β (IL-1β) [160, 161].
It is remarkable that, although the data presented, endothelial function seems to be normal in
CCC patients without heart failure, as measured by increases in blood flow in response to
acetilcholine and sodium nitroprusside [162]. A normal endothelial function has also been
found using pulse plethysmography in 40 asymptomatic patients with Chagas’ disease
compared with healthy controls, although a prothrombotic and proinflammatory state has
been noted in Chagas’ disease patients [163].
4. A combined theory that could explain the pathogenic mechanism in
chronic chagasic myocarditis
With the perpetuation of inflammation, necrosis and scarring fibrosis, damage to all histolog‐
ical components of myocardium occurs. Damage to contracting myocardial fibers determines
contractile failure as well as electrophysiological disturbances. Conduction system, nervous
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autonomic system and microvasculature are also damaged and as a consequence they cause
further damage to contractile myocardium and produce electrical instability. Figure 3
illustrates with a flow chart the interactive network of different elements in the pathogenesis
of CCC.
Figure 3. Schematic representation of the integrated theory of multiple factors that determine myocardial damage in
CCC.
5. Conclusions
As shown across the sections of this chapter, the numerous hypothesis about pathogenic
pathways of CCC have supporting data and pitfalls. All hypothesis finally interact with each
other, giving us the idea that none of these theories explains the development of CCC by itself.
Rather, it seems more feasible that all of these conform a network of damaging elements, and
that all elements cause and/or enhances each other. The triggering element is obviously the
interaction between parasite and host’s immune system. Cell parasitism, the inflammatory
process and consequent necrosis and fibrosis cause damage to contracting myocardium,
autonomic system, conduction system and microcirculation. Autonomic damage causes
impaired regulation of microvasculature and further alterations in blood flow. Ischemia causes
more myocardial damage. Necrosis exposes intracellular epitopes and causes autoantibodies
production, with more necrosis, fibrosis and so on. It seems that, if adequate down modulator
immune mechanisms work properly, this vicious circle stops and patients do not develop
cardiomyopathy, rather they remain in an indeterminate form lifelong.
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